TriplePoint Venture Growth (NYSE: TPVG) has received mixed analyst ratings over the past three months, with a majority leaning towards 'Somewhat Bearish'. The average 12-month price target has decreased from $9.25 to $8.38. Analysts from firms like Keefe, Bruyette & Woods, Piper Sandler, and Wells Fargo have lowered their ratings and price targets. Despite strong financial metrics like a high net margin and ROE, TPVG faces challenges with its ROA and revenue growth compared to industry peers.